| Mollie Catherine Hamilton, MD | |
|
1204 W Main St, Charlottesville, VA 22903-2824 | |
| (434) 924-0123 | |
| Not Available |
| Full Name | Mollie Catherine Hamilton |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 1204 W Main St, Charlottesville, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053760488 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | LL39470 (South Carolina) | Secondary |
| 208000000X | Pediatrics | 0101273833 (Virginia) | Primary |
| Entity Name | University Of Virginia Physicians Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033138250 PECOS PAC ID: 4880590728 Enrollment ID: O20040102000780 |
News Archive
On New Year's Day this coming Sunday, we will once again be waiting to see whereabouts in Austria the first baby is born safe and sound to be our "New Year's Baby 2017".
Experts at the European Committee on Antimicrobial Susceptibility Testing, who define the optimal drug concentrations to inhibit the growth of pathogens, have found that genetic methods cannot yet be used to test for susceptibility in a number of important bacterial species.
"Calling the subjugation of women a threat to American security, U.S. Secretary of State Hillary [Rodham] Clinton made a vibrant plea to give equal rights to women around the world," during a speech a the U.N. on Friday, Agence France-Presse reports.
Threshold Pharmaceuticals, Inc., today announced two preclinical presentations on its clinical stage hypoxia-activated prodrug, TH-302, at the American Association for Cancer Research Translational Cancer Medicine Meeting, being held July 11 to 14, 2010, in San Francisco, CA. The preclinical presentations describe new findings regarding the efficacy of TH-302 when combined with multi-kinase inhibitors that inhibit VEGF signaling, as well as the efficacy of TH-302 in combination with gemcitabine in models of pancreatic cancer.
IDIBELL Researchers of the Neuro-Oncology Unit of Bellvitge University Hospital - Catalan Institute of Oncology, led by Dr. Jordi Bruna, have successfully tested a new molecule capable of preventing the development of peripheral neuropathy induced by chemotherapy in cancer patients, especially in colon cancer cases, the third most common neoplasm in the world.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mollie Catherine Hamilton, MD Po Box 9007, Charlottesville, VA 22906-9007 Ph: () - | Mollie Catherine Hamilton, MD 1204 W Main St, Charlottesville, VA 22903-2824 Ph: (434) 924-0123 |
News Archive
On New Year's Day this coming Sunday, we will once again be waiting to see whereabouts in Austria the first baby is born safe and sound to be our "New Year's Baby 2017".
Experts at the European Committee on Antimicrobial Susceptibility Testing, who define the optimal drug concentrations to inhibit the growth of pathogens, have found that genetic methods cannot yet be used to test for susceptibility in a number of important bacterial species.
"Calling the subjugation of women a threat to American security, U.S. Secretary of State Hillary [Rodham] Clinton made a vibrant plea to give equal rights to women around the world," during a speech a the U.N. on Friday, Agence France-Presse reports.
Threshold Pharmaceuticals, Inc., today announced two preclinical presentations on its clinical stage hypoxia-activated prodrug, TH-302, at the American Association for Cancer Research Translational Cancer Medicine Meeting, being held July 11 to 14, 2010, in San Francisco, CA. The preclinical presentations describe new findings regarding the efficacy of TH-302 when combined with multi-kinase inhibitors that inhibit VEGF signaling, as well as the efficacy of TH-302 in combination with gemcitabine in models of pancreatic cancer.
IDIBELL Researchers of the Neuro-Oncology Unit of Bellvitge University Hospital - Catalan Institute of Oncology, led by Dr. Jordi Bruna, have successfully tested a new molecule capable of preventing the development of peripheral neuropathy induced by chemotherapy in cancer patients, especially in colon cancer cases, the third most common neoplasm in the world.
› Verified 5 days ago
Mr. Michael Douglas Dickens, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1011 E Jefferson St, Charlottesville, VA 22902 Phone: 434-296-9161 Fax: 434-296-1036 | |
Linda A. Waggoner Fountain, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1204 W Main St, Charlottesville, VA 22903 Phone: 434-924-0123 Fax: 434-243-3300 | |
Marion Elizabeth Szwedo, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1011 E Jefferson St, Charlottesville, VA 22902 Phone: 434-296-9161 Fax: 434-977-6068 | |
Dr. Gregory Rees Sturz, DO, PHD Pediatrics Medicare: Medicare Enrolled Practice Location: 1215 Lee St, Box 800501, Charlottesville, VA 22908 Phone: 494-942-5321 Fax: 434-982-3816 | |
Anne C Butz, LCSW Pediatrics Medicare: Medicare Enrolled Practice Location: 1204 W Main St, Charlottesville, VA 22903 Phone: 434-924-5321 Fax: 434-244-4412 | |
Jessica C Di Zio, PNP Pediatrics Medicare: Medicare Enrolled Practice Location: 1215 Lee St, Charlottesville, VA 22908 Phone: 434-924-1761 Fax: 434-982-3561 | |
Brooke D. Vergales, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1215 Lee St, Charlottesville, VA 22908 Phone: 434-924-2335 Fax: 434-982-0796 |